Media coverage about Henry Schein (NASDAQ:HSIC) has trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Henry Schein earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 47.3414038591134 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Henry Schein (NASDAQ HSIC) opened at $71.75 on Friday. The firm has a market capitalization of $11,452.96, a PE ratio of 20.68, a P/E/G ratio of 1.87 and a beta of 1.00. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.55 and a quick ratio of 0.86. Henry Schein has a 12 month low of $65.28 and a 12 month high of $93.50.

HSIC has been the topic of several analyst reports. Morgan Stanley lowered Henry Schein from an “equal weight” rating to an “underweight” rating and set a $88.00 target price on the stock. in a report on Wednesday, December 6th. Piper Jaffray Companies reissued a “buy” rating and set a $78.00 target price on shares of Henry Schein in a report on Wednesday, December 27th. Craig Hallum raised Henry Schein from a “hold” rating to a “buy” rating in a report on Tuesday, November 7th. Credit Suisse Group reaffirmed a “neutral” rating and issued a $80.00 price objective (down from $87.50) on shares of Henry Schein in a research note on Tuesday, November 28th. Finally, Zacks Investment Research lowered Henry Schein from a “hold” rating to a “sell” rating in a research note on Monday, November 13th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $84.23.

In related news, Director Barry J. Alperin sold 5,796 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $70.76, for a total value of $410,124.96. Following the sale, the director now directly owns 48,172 shares of the company’s stock, valued at $3,408,650.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.19% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Henry Schein (HSIC) Getting Somewhat Positive News Coverage, Analysis Finds” was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Insider Buying and Selling by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with's FREE daily email newsletter.